InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-32.4%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Chin Mark, Directeur. Director active across 4 companies, notably IMARA Inc.. Aggregated, 14 filings have been recorded. Split: 2 buys · 1 sell. Total volume traded: €18.5m. History available since 16 July 2021. The latest transaction was filed on 8 March 2024 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations14 total
424 shares0Common StockSEC:0000950170-24-029439:0
1,072 shares0Common StockSEC:0000950170-24-000959:0
5,000 shares0Common StockSEC:0001209191-23-056794:0
3,035 shares0Common StockSEC:0001209191-23-051148:0
18,656 shares0Common StockSEC:0001209191-23-041673:0
15,853 shares0Ordinary SharesSEC:0001209191-23-037405:0
18,285 shares0Common StockSEC:0001209191-23-022794:0
36,798 sharesOrdinary SharesSEC:0001209191-22-039313:0
1,745,761 shares@ US$3.053.40% mcap100.0% of flowCommon StockSEC:0000899243-22-015542:0
66,831 shares0Common StockSEC:0001140361-22-012917:0
1,433,261 sharesCommon StockSEC:0001140361-21-034645:0
1,433,261 sharesCommon StockSEC:0001140361-21-034645
1,333,333 shares@ US$6.0050.0% of flowCommon StockSEC:0001209191-21-048395:0
Ideal exit: 12 Apr 2022 (T+270)
1,333,333 shares@ US$6.0050.0% of flowCommon StockSEC:0001209191-21-048395
Ideal exit: 12 Apr 2022 (T+270)
14 of 14 declarations
About Chin Mark
Mark Chin is a Director at Imara Inc., Pyxis Oncology, Inc., and Iterum Therapeutics plc. He is involved in overseeing activities and strategic decision-making for these companies. His experience in the pharmaceutical sector contributes to the direction and growth of the organizations. As a board member, he ensures governance and compliance of practices.
